Skip to main
PHVS

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 70%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris is a late-stage biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE). The company's lead candidate, deucrictibant, has shown positive data in Phase 2 studies for both prophylaxis and on-demand treatment of HAE attacks, and the company is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks. With strong data supporting the efficacy and safety of deucrictibant, and a clear path towards potential regulatory approval, Pharvaris has the potential to be a leader in the HAE treatment market.

Bears say

Pharvaris is a late-stage biopharmaceutical company that is pursuing a clinically therapeutic target with small molecules for the treatment of hereditary angioedema (HAE). Despite positive data in both Phase 2 studies and promising results in the ongoing pivotal Phase 3 studies, Pharvaris's stock price may be dampened by a competitive landscape in the HAE market and a delayed launch timeline for their drug deucrictibant, which may impact their potential peak annual revenues, estimated to be around $600 million. Additionally, there may be financial concerns regarding the company's operating expenses, which were higher than expected in the last quarter.

Pharvaris B.V. (PHVS) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 70% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 10 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.